Archer Paul

MD - Radiation Oncologist

[Archer Paul @ArcherPaul_]

Salvage Stereotactic Reirradiation for Local Recurrence in the Prostatic Bed After Prostatectomy: A Retrospective Multicenter Study

https://t.co/zw7R0wKwSx
In press in @EurUrolOncol

Median PFS: 23.5 mo
3-yr grade ≥2 late GU or GI toxicity: 18%

[Gustavo @gusviani]

🔥 PCS-9: SBRT + ENZA Doubles Disease Control in Oligometastatic CRPC @OncoAlert @dr_cury

🎯 Objective
• Evaluate whether adding SBRT to ADT + enzalutamide ⬆️ outcomes in oligometastatic CRPC (≤5 mets)

🏥 Methods
• Ph 2, randomized, 13 Canadian centers.
• 100 men with oligometastatic CRPC
• Arm A: ADT + ENZA;
Arm B: ADT + ENZA + SBRT
• SBRT: 24–60 Gy in 2–8 fractions to all metastatic sites

📊 Results
• Median rPFS: 4.6 vs 2.3 y (HR 0.48; p=0.014)
• Time to next systemic therapy: 5.1 vs 2.9 y
• No grade 4/5 events; toxicity comparable

➡️ SBRT + ENZA marks a paradigm shift in oligometastatic CRPC management

[JAMA Oncology @JAMAOnc]

Induction-concurrent chemotherapy does not significantly improve progression-free survival compared with concurrent-adjuvant chemotherapy in high-risk N2–3 nasopharyngeal carcinoma. https://t.co/mFseLzyjAF

[Adam B. Weiner, MD @Adam_Weiner535]

🚨Epidemiology of High-risk Biochemical Recurrence After Primary #ProstateCancer Treatment🚨

🙍‍♂️🙍‍♂️17K population-based study

👉 Using BCR risk groups continues to show promise to personalize treatment intensity for future patients

@EurUrolOncol

🔗https://t.co/oOyQnGrLTL

@urotoday @renalandurology @UrologyTimes

[Yakup Ergün @dr_yakupergun]

#ASCO25 @NEJM
BREAKWATER: Encorafenib + cetuximab + mFOLFOX6 vs standard care in 1L BRAF V600E mCRC

PFS➡️12.8 vs 7.1 mo✅️
OS➡️ 30.3 vs 15.1 mo✅️👏

💥For one of the hardest-to-treat mCRC subtypes, this triplet shows substantial survival benefit.

https://t.co/dzjsTD9wiF

[JAMA Oncology @JAMAOnc]

Viewpoint discusses how "skimming the median" can exaggerate survival gains in clinical trials, underscoring the need to critically evaluate Kaplan-Meier curves alongside hazard ratios. https://t.co/F8NeDGb89W

[Piet Ost @piet_ost]

📢 STORM trial breaking results at #ESTRO25!

🧪 MDT vs ENRT+MDT for nodal oligorecurrent PCa.

🧬 ENRT+MDT:
✅ Superior bRFS (57% vs 41%, p=0.014)
✅ Superior pelvic control (lrRFS 85% vs 62%, p=0.006)
✅ Superior MFS (76% vs 63%, p=0.06)
❌ No increase in ≥G2 GU/GI toxicity

[Michael Hofman @DrMHofman]

Incredible prognostic power of PSMA PET from the updated PROMISE large international registry (PPP2): 3 and 5-yr survival data. Superior to NCCN risk score.

Data across initial stage, biochemical recurrence, "non-metastatic" castration-resistant, mSPC, MCRPC !!

Just out in @Uroweb European Urology:
https://t.co/O8jCV5yHxg

Free software https://t.co/V99R6pHqgc

[The Daily Dunk @dailydunkfr]

Contrer à cette hauteur à 2 mains, c'est athlétiquement irréel, c'est Diamant Blazi 🇫�

[Gustavo @gusviani]

🚨 Who needs more than standard ☢️ + ADT in high-risk prostate cancer? 🚨@OncoAlert

🔎 Objective: Identify HRLPC patients with poor outcomes on ☢️+ long-term ADT

🧪 Methods:
✅ 3,604 👥 from 10 RCTs
✅ Evaluated Metastasis-Free Survival (MFS) & Overall Survival (OS)
✅ Risk factors (RFs):
🔹 Gleason ≥8
🔹 PSA >20 ng/mL
🔹 T3–T4 disease
🔹 cN1 (lymph node involvement)
📊 Results:
⚠️ 5-yr MFS:
🔸 83% (1 RF)
🔸 78% (2–3 RFs)
🔸 67% (cN1)
⚠️ 10-yr OS:
🔸 67% (1 RF)
🔸 60% (2–3 RFs)
🔸 47% (cN1)
🚀 Clinical Takeaway: 👥 with 2+ RFs or cN1 may need treatment intensification!

#RadOnc #ProstateCancer

[Archer Paul @ArcherPaul_]

ESOPEC trial - Game changer for resectable esophageal adenocarcinoma

Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer | New England Journal of Medicine https://t.co/WeawL6jppi

[Archer Paul @ArcherPaul_]

Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Recurrent Small Hepatocellular Carcinoma: A Randomized, Open-Label, Controlled Trial | Journal of Clinical Oncology https://t.co/rdDXH5D4FV

[Gustavo @gusviani]

7/ The role of ☢️:
•For patients who skipped axillary surgery, incidental radiation doses to the axilla during whole-breast radiotherapy provided sufficient regional control.
•Axillary level I received ~85% of the prescribed dose for the breast, while level II received ~15%.

[Gustavo @gusviani]

Do all early-stage breast cancer patients need axillary surgery? The INSEMA trial challenges this long-standing practice, showing that skipping sentinel lymph node biopsy (SLNB) may be safe for select patients. ☢️ plays a key role. Let’s dive into the data. 🧵 1/13#RadOnc #BreastSurgery”

[SBRT memes for hypofractionated teens @sbrtmemes]

Urologists in 2026 when sbrt takes over
#handitover
#comingforbladdernext
#donth8ablate
#radonc

[Alison Tree 💙 @alison_tree]

Tell me again why we can’t use renal SBRT in the UK?!? 100% local control is hard to beat. Masterclass by @_ShankarSiva #ASTRO24

[Keith Siau @drkeithsiau]

I love Twitter 😅😂

[Luis Moreno Sánchez @radioncoluis]

Locoregional Ablative Radiation Therapy for Patients With Breast Cancer Unsuitable for Surgical Resection.
https://t.co/sNyOkGbW0Q

[Arndt Vogel @ArndtVogel]

🔥PLENARY Session #ASCO24🔥
Perioperative chemotherapy (FLOT) to neoadjuvant chemoradiation (CROSS) in patients with adenocarcinoma of the esophagus
🔎 ESOPEC phase III trial, 438 patients
👉R0 180 vs 171
👉pCR 17 vs 10%
👉mOS 66 vs 37 mo
👉3yr OS: 57.4 vs 50.7%
🧐FLOT improves OS compared to CROSS
@myESMO

[Chris Parker @PCaParker]

Good to see RADICALS-HD in print. THanks to numerous colleagues and collaborators over 20 years https://t.co/EfrhJsm4Ce

[Archer Paul @ArcherPaul_]

Quand tu fais ta première nasofibro

[SBRT memes for hypofractionated teens @sbrtmemes]

Radonc resident learning their first scope (it's me)
#radonc